BRIEF-Ibio And Astralbio Unveil Obesity Program With Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Reuters
06-24
BRIEF-Ibio And Astralbio Unveil Obesity Program With Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

June 24 (Reuters) - iBio Inc IBIO.O:

  • IBIO AND ASTRALBIO UNVEIL OBESITY PROGRAM WITH NOVEL AMYLIN AGONIST ANTIBODY DEMONSTRATING PROMISING IN VIVO RESULTS

  • IBIO INC - ANTIBODY-BASED AGONISTS SHOW POTENTIAL FOR OBESITY AND CARDIOMETABOLIC DISEASES

  • IBIO INC - AMYLIN RECEPTOR AGONIST ANTIBODY REDUCES FOOD INTAKE IN MOUSE MODEL

Source text: ID:nGNXb0L8SQ

Further company coverage: IBIO.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10